I have loved your posts for over a year and for the first

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps TechGuru #51453
708
I have loved your posts for over a year and for the first time I disagree. When you state that the reason it can’t be (us) Leronlimab because of the OWS not helping us.

We need OWS now for Grant monies to increase our production across the whole of the country and then the world. OWS can most definitely help with that. We also need production facilities approved to do that. Trump just in the last few weeks went to a new opening Fuji biological production plant that might need customers like us. Do you think he put them on notice that they might be soon working for him and the pandemic production of future drugs?

For Trump to reign the “ Art of the Deal “ it will be about him finding this little company and helping this little undersized fledgling company ramp up production through OWS by not only helping to increase production and securing it with a rather large grant of monies. He will complete the deal with an prearranged agreement that the First 50 million Or whatever doses will stay in the USA until the massively increased production can ramp up to meet USA needs. My guess is Trumps selling point is he has made the complete “ Art of the Deal “ like no one else could to help our country. He pushed the FDA to approve and he set up our little company to succeed with grant monies and facilities to do it in. He secured a deal that allows wide spread use in USA first. At least initially until the production can be scaled to supply the world.

Have you wondered why an announcement on Sunday is happening? Could it be that the time difference in the U.K. is 6 hours sooner and a Monday announcement will be really late after a possible U.K. Approval? Trump would want to be first and have all the attention and to let the world know he secured the first couple of months of production for our country.

For me... this is how I have seen Trump helping (us) Cytodyn all along when the time arrived.

It’s Has arrived in my book and today is our day! We are all a part of saving lives. We should proudly tell the ones we haven’t already of our small part in helping the OTC company succeed and the future of saving lives of many many people all over the world. Yes... my cup runneth over! It was always over half full. It’s what I choose to believe. If it’s finally coming true then we all will be celebrating! Make mine a double and keep them coming...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Millrose Faces Class Action: Blame Game in Motion

Updated Category News Views 10

Millrose Properties: A Realty Ruckus Unfolding Sometimes, in the world of stocks, it feels like you're two steps ahead of the scam or already knee-deep in trouble. Millrose Properties, Inc. struck a rather sour chord recently with an 8.53% stock drop, leaving investors feeling the burn. Here's the juice: a securities fraud class action is in motion, and if you're holding...

Continue Reading
St. Croix Financial Hub: Game Changer or Fluff?

Updated Category News Views 7

You know, sometimes it feels like the financial world gets more tangled than a fishing line on a windy beach. This latest spiel coming out of St. Croix with all its big names and lofty promises—Governor Bryan’s 3rd Wall Street Financial District Hub Initiative—seems like one of those, but maybe it’s got more meat than hype. Half the pitch sounds like your typical...

Continue Reading
Cesar Alvarez Honored with Prestigious Miami Award

Updated Category News Views 4

Cesar Alvarez's Legacy Honored in Miami The Greater Miami Chamber of Commerce's 2026 Sand in My Shoes® Award has found its latest recipient in Cesar L. Alvarez, the Senior Chairman of Greenberg Traurig, P.A. It wasn't just a ceremony—this was a gathering of more than 800 of Miami's business and community power players on October 15, 2026. And man, did it shine a bright...

Continue Reading
CTG Data Breach Sparks Class Action Investigation

Updated Category News Views 11

CTG Faces Scrutiny Over Recent Data Breach Ah, the thrills and spills of the digital age—yet another company stumbling headfirst into a data breach mess. This time, it’s Computer Task Group (CTG) taking center stage, with its IT systems compromised and personal info slipping through the cracks. On September 26, 2026, an unwelcome guest rooted around their network,...

Continue Reading
Lazard's Q3 2026: Surging Revenue, Waning Net Income

Updated Category News Views 0

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Continue Reading
Mario Lopez: Homegrown Star Hosts Birthday Tequila Bash

Updated Category News Views 6

Not every day do you get a celeb hitting their home turf just to throwback with fans, but that's Mario Lopez for you. Coming right into San Diego for his birthday month, Lopez isn't just sipping tequila—he’s signing it. Swing by Old Town Tequila and Keg N Bottle this October 24 if you want a bottle of Casa México Tequila adorned with a little star power. Sips,...

Continue Reading
New Blood Joins Board: A Power Move for Bank of America

Updated Category News Views 3

A Fresh Breeze in the Boardroom Bank of America isn't sitting still. They're shaking things up by bringing in Jim Fitterling and Bill Thomas. Now, why’s that a big deal for those watching NYSE:BAC? Well, these guys pack heavy resumes, and their experience could steer the ship with precision across turbulent financial waters. The Minds Behind the Names Let's chew the fat...

Continue Reading
Side Bolsters Art Division with Roboto Acquisition

Updated Category News Views 7

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

Continue Reading
McLean Guide: Turning Culture Data into Real Action

Updated Category News Views 4

Unlocking the Potential of Culture Measurement In the corporate jungle, culture is like oxygen. You don’t see it, but you sure as heck feel it when it’s missing or toxic. McLean & Company just dropped a new guide that promises to map out the invisible by measuring organizational culture. Now, you might say, 'Cultural alignment sounds like consultant mumbo-jumbo.' But...

Continue Reading
Genedata's AI Push: A Biotech Game-Changer?

Updated Category News Views 1

A Glimpse into Genedata's Bold AI Integration So, here's a heck of an ambitious move in the biotech sphere with Genedata dropping the news about their integration of NVIDIA's BioNeMo AI models into their R&D workflows. These folks at Genedata are really riding the tech wave, offering up the new RFD4-Proteina release in what they call 'binder design' for biologics...

Continue Reading

Top 5 Most Recently Viewed Articles

Acer Gains Ground in 2026 Sustainability Rankings

Updated Category News Views 90

Acer's New Spotlight in Global Sustainability Step aside, because Acer's making waves again in the sustainability arena. They're on the Dow Jones Best-in-Class World Index, not for the first time but the second, and that's no fluke. Only four companies got the nod in their category—Computers & Peripherals and Office Electronics—and getting full marks in Transparency &...

Continue Reading
Huadong Medicine Showcases Breakthroughs in Cancer Therapy

Updated Category News Views 168

Huadong Medicine's Groundbreaking Phase I Study Results Huadong Medicine Co., Ltd. has recently announced some exciting developments regarding their innovative treatment known as HDM2005. This groundbreaking antibody-drug conjugate (ADC) specifically targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) and is making waves in the clinical landscape for certain...

Continue Reading
American Rebel and CEO Shine at NHRA FallNationals Fan Fest

Updated Category News Views 76

American Rebel CEO to Highlight NHRA FallNationals The vibrant atmosphere of the NHRA FallNationals is set to be electrifying with American Rebel Holdings, Inc. (NASDAQ: AREB) participating in the Pre-Stage Fan Fest. This event will allow fans to engage closely with the racing community and enjoy exciting activities. Exciting Family-Friendly Activities Andy Ross, the...

Continue Reading
Investors Should Act Promptly to Protect Their AXSM Shares

Updated Category News Views 220

Kuehn Law Stands Up for AXSM Investors Kuehn Law, a dedicated shareholder litigation law firm, is currently investigating the actions of certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM). This investigation aims to discern whether there have been potential breaches of fiduciary duty to the shareholders, which could have serious consequences....

Continue Reading
Celebrating Excellence: Willig, Williams & Davidson Lawyers Honored

Updated Category News Views 122

Celebrating Excellence in Labor Law Pennsylvania's Willig, Williams & Davidson has earned notable recognition, reflecting their long-standing commitment to labor and employment law. A total of 19 attorneys from this esteemed firm have been acknowledged in the elite 2026 edition of The Best Lawyers in America. This prestigious list has become synonymous with legal...

Continue Reading